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Effect of CMV Serology on Outcome After Clinical 
Intestinal Transplantation 
H. Furukawa, S. Kusne, K. Abu-Elmagd, M. Green, J. Reyes, T.E. Starzl, and S. Todo 
OVER the last 5 years, intestinal transplantation has become a feasible therapeutic option for patients 
with irreversible intestinal failure. 1 Cytomegalovirus (CMv) 
infection was shown to be the most frequent viral infection in 
the intestinal transplant recipients and to be related to high 
mortality and morbidity.2.3 In this study, we analyzed the effect 
of CMv serology of donors and recipients on the outcome of 
patient and graft survival after intestinal transplantation. 
MATERIALS AND METHODS 
From May 1990 to September 1995, 76 intestinal transplantations 
were performed in 72 patients (25 isolated intestine [I], 35 intesti-
nal and liver [IlL], and 12 multivisceral [MV]) at our center. There 
were 31 adults and 41 children. with ages ranging from 6 months to 
58 years. Postoperative immunosuppression was with tacrolimus 
(FK 506), steroids. and in selected cases azathioprine (AZA). 
Donor and recipient procedures are described elsewhere.4 Tissue 
sampling for CMV was performed when it was clinically indicated. 
Invasive CMV disease was diagnosed by histopathologic findings 
and/or by isolation of the virus from tissue specimens. Tissue 
invasion was determined by detection of typical CMV inclusion 
bodies along with predominant neutrophilic infiltration and/or 
unequivocal immunoperoxidase staining of the virus. Isolation of 
the virus was confirmed by either the shell vial technique or by 
standard culture. 
Fifty-three of 72 recipients received gancic10vir prophylaxis (5 
mg/kg twice a day for 2 to 3 weeks in children, and for 3 weeks to 
3 months in adults) followed by acyclovir for several months. CMV 
disease was treated either by ganciclovir (5 mg/kg twice a day), 
foscarnet (60 mg/kg three times a day), CMV immunoglobulin (100 
mg/kg every 2 weeks). or a combination of these agents. The effect 
of donor and recipient CMV serology on patient and graft survival 
was studied. Chi-square. Kaplan-Meier. and log rank tests were 
used for statistical analysis. Statistical significance was achieved if 
the P value was less than 0.05. 
RESULTS 
Twenty-four (33%) of 72 recipients developed CMv dis-
ease after transplantation during a I-month to 5-year 
follow-up period. In these 24 patients. CMv disease oc-
curred a total of 52 times; 14 patients developed only one 
episode and 10 patients developed two to eight episodes of 
CMv disease. The type of CMv diseases seen were graft 
enteritis (n = 43), native gastroduodenitis (n = 3), hepatitis 
(n = 2), pneumonia (n = 3), and retinitis (n = 1). Table 1 
shows the frequency of CMv disease and 4 year patient and 
graft actuarial survival rates, differentiated by the CMV 
serology of the donor and recipient. Comparing survival 
based on donor CMV serology showed that patients who 
received CMV-seropositive intestinal grafts had signifi-
cantly worse patient and graft survival than patients who 
received CMV-seronegative grafts (P = 0.02). However. 
recipients' CMV serology did not affect outcome. The four 
year actuarial patient and graft survival rates of the CMV 
seronegative recipients were 51 and 41 %. The actuarial 
patient and graft survival of the CMv seropositive recipi-
ents were 33% and 29%. 
DISCUSSION 
CMV disease occurs more frequently after intestinal trans-
plantation than other types of whole organ transplantation. 
The increased incidence of CMv disease in intestinal 
transplantation may be related to higher levels of immuno-
suppression needed to prevent rejection.1 This study show~ 
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Four Year Survival 
Median InCidence of 
Follow·up CMV Disease Patient Graft 
32 mo 0 62% 53% 
34 mo 56% 43% 37% 
19 mo 58% 32% 20% 
17 mo 44% 16%' 15% 
32 mo 20% 57% 49% 
19 mo 54% 27%" 17%" 
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that patients who receive CMV-positive grafts had signifi-
cantly higher morbidity and mortality than the patients who 
received CMV -negative grafts. Although CMV disease was 
not necessarily a direct cause of the graft failure or patient 
death, CMV infection itself or management of CMV infec-
tion possibly induced subsequent rejection and rejection-
related morbidity and mortality.s To avoid CMV related 
mortality, CMV-seropositive grafts should not be used for 
intestinal transplantation unless the candidate are in dire 
need of life-saving organ (liver) transplantation. 
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